Browse diseases

…Introduction To evaluate current treatment patterns for systemic sclerosis-associated interstitial lung disease (SSc-ILD) and identify factors influencing therapy initiation, switching,…

…Introduction Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a progressive fibrotic disorder and a leading cause of morta…

…Introduction Identifying distinct radiological phenotypes in systemic sclerosis-associated interstitial lung disease (SSc-ILD), namely a predominantly inflammatory and a predominantly fibrot…

…Introduction Nintedanib slows progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD), but its tolerability is a potential concern.Material and Metho…

… linked to mortality in idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis (RA)-associated ILD. Here, we evaluated the value of CT-derived…

…Introduction The presence and severity of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is associated with increased pulmonary vascular volume (PVV), q…

…Introduction Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is one of the leading causes of mortality in patients with SSc.…

…udies, randomized controlled trials assessing their efficacy in systemic sclerosis-associated interstitial lung disease (SSc-ILD) showed mixed results. Therefore, we assessed the impact of VVDs…

…pected to be stable on subsequent HRCT imaging in patients with idiopathic pulmonary fibrosis (Shi Y, et al. Artif Intell Med. 2019;100:101709). The Single-s…

…pport the clinical investigation of MSC-based interventions for SSc-ILD.…

…Background Nintedanib slows progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD), but its tolerability is a potential concern.Methods This multi…

… microvascular changes in nailfold capillaries in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who received nintedanib or placebo in a sub-study of the SENSCI…